COMPLEMENT-MEDIATED KIDNEY DISEASE
Clinical trials for COMPLEMENT-MEDIATED KIDNEY DISEASE explained in plain language.
Never miss a new study
Get alerted when new COMPLEMENT-MEDIATED KIDNEY DISEASE trials appear
Sign up with your email to follow new studies for COMPLEMENT-MEDIATED KIDNEY DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New siRNA drug aims to tame kidney disease
Disease control Recruiting nowThis Phase 2 study is testing a new drug called ADX-038 in 45 adults with complement-mediated kidney diseases, such as IgA nephropathy and C3G. The drug is an siRNA that targets the complement system, which is overactive in these conditions. Researchers are checking if it is safe…
Matched conditions: COMPLEMENT-MEDIATED KIDNEY DISEASE
Phase: PHASE2 • Sponsor: ADARx Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill CMS-D017 enters first human safety trials
Knowledge-focused Recruiting nowThis early-stage study tests a new drug called CMS-D017 in 88 healthy adults to see if it is safe and how the body processes it. The drug is being developed for two rare conditions: paroxysmal nocturnal hemoglobinuria (a blood disorder) and complement-mediated kidney disease. Par…
Matched conditions: COMPLEMENT-MEDIATED KIDNEY DISEASE
Phase: PHASE1 • Sponsor: Shenzhen Kangzhe Biotechnology Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC